- GlaxoSmithKline Plc’s cancer treatment Zejula met the main goal of helping patients with ovarian cancer live longer without their disease worsening in a late-stage study, the company said on Monday.
The study, called PRIMA, tested the treatment as maintenance therapy in women who have undergone platinum-based chemotherapy and met the main goal for women regardless of their biomarker status, GSK said. “Zejula’s potential to expand PARP use beyond BRCAm patients, was a key justification for its Tesaro acquisition and this required a positive outcome for Zejula in the PRIMA study,” Jefferies analysts said.PARP inhibitors are a class of drugs which work by blocking enzymes involved in repairing damaged DNA, thereby helping to kill cancer cells, and are a growing focus for drug research, with potential for use in breast, lung and prostate cancers.